SHR-1316 + Carboplatin + Etoposide + Placebo
Phase 3UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small Cell Lung Cancer
Conditions
Extensive-stage Small Cell Lung Cancer
Trial Timeline
Dec 30, 2018 → Dec 1, 2023
NCT ID
NCT03711305About SHR-1316 + Carboplatin + Etoposide + Placebo
SHR-1316 + Carboplatin + Etoposide + Placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Extensive-stage Small Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT03711305. Target conditions include Extensive-stage Small Cell Lung Cancer.
What happened to similar drugs?
0 of 6 similar drugs in Extensive-stage Small Cell Lung Cancer were approved
Approved (0) Terminated (1) Active (5)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
🔄BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
17
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03711305 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Extensive-stage Small Cell Lung Cancer